S. Evers
Oncology · 2016
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 30 citations into it
- Immunology — 23 citations into it
Whom S. Evers trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- D. Pardoll (in Oncology)
Papers from S. Evers's perspective
Ordered by how strongly the researchers S. Evers trusts endorse each paper. Same corpus, a different order for every researcher.
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
- PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
- Signatures of mutational processes in human cancer (Nature)
- An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
- The future of immune checkpoint therapy (Science)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (Journal of Clinical Oncology)
- Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)